MALALAI YUSUFZAI: Open Payments
NPI 1740751247 · WEST SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,548 in 122 payments from 22 companies in 2025. Trend: 2023 $3,162 · 2024 $2,861 · 2025 $2,548
Food & beverage: $2,548
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $400 |
| AstraZeneca Pharmaceuticals LP | 17 | $359 |
| Novo Nordisk Inc | 19 | $348 |
| JAZZ PHARMACEUTICALS INC. | 11 | $279 |
| GlaxoSmithKline, LLC. | 8 | $213 |
| Aimmune Therapeutics, Inc. | 6 | $159 |
| Lilly USA, LLC | 10 | $149 |
| Exact Sciences Corporation | 3 | $87 |
| SANOFI-AVENTIS U.S. LLC | 4 | $73 |
| Organogenesis Inc. | 2 | $65 |
Products named: XYWAV, Ozempic, UBRELVY, TRELEGY ELLIPTA, ZENPEP, BREZTRI, Rybelsus, LINZESS.
Industry payments across CA — which companies pay providers there.
